Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Secondary Malignant Neoplasm of Prostate: early-phase trial registry

1 of 1 indexed Secondary Malignant Neoplasm of Prostate trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Secondary Malignant Neoplasm of Prostate: 1 US clinical trial tracked, 1 recruiting.

Secondary Malignant Neoplasm of Prostate is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Case Comprehensive Cancer Center, running 1 of these trials.

Enrollment posture brief

Registry condition secondary-malignant-neoplasm-of-prostate

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Secondary Malignant Neop (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Secondary Malignant Neoplasm of Prostate

Secondary Malignant Neoplasm of Prostate lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Secondary Malignant Neoplasm of Prostate on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Secondary Malignant Neoplasm of Prostate is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on Secondary Malignant Neoplasm of Prostate records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Metastasis directed radiotherapy (MDRT) Radiation
1 trials
Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT) Other
1 trials
Androgen receptor signaling inhibitor (ARSI) Drug
1 trials
Androgen deprivation therapy (ADT) Drug
1 trials

US sites by state

Facility locations filed on Secondary Malignant Neoplasm of Prostate trials. A trial with sites in several states counts in each.

Wisconsin 1 trials
Ohio 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Secondary Malignant Neoplasm of Prostate page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Secondary Malignant Neoplasm of Prostate trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Case Comprehensive Cancer Center sponsors the most Secondary Malignant Neoplasm of Prostate trials on record, review their full trial history before evaluating a specific study. See Case Comprehensive Cancer Center's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Secondary Malignant Neoplasm of Prostate condition card totals 1 registered trials; most-linked intervention Metastasis directed radiotherapy (MDRT); top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.